Lactoferrin-loaded nanostructured lipid carriers (NLCs) as a new formulation for optimized ocular drug delivery
Por favor, use este identificador para citas ou ligazóns a este ítem:
http://hdl.handle.net/10347/29014
Ficheiros no ítem
Metadatos do ítem
Título: | Lactoferrin-loaded nanostructured lipid carriers (NLCs) as a new formulation for optimized ocular drug delivery |
Autor/a: | Varela Fernández, Rubén García Otero, Xurxo Díaz Tomé, Victoria Regueiro Lorenzo, Uxía López López, María Teresa González Barcia, Miguel Lema Gesto, María Isabel Otero Espinar, Francisco Javier |
Centro/Departamento: | Universidade de Santiago de Compostela. Departamento de Cirurxía e Especialidades Médico-Cirúrxicas Universidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica |
Palabras chave: | Nanostructured lipid carriers (NLC) | Double emulsification-solvent evaporation method | Lactoferrin | Ocular drug delivery | Topical ophthalmic administration | Keratoconus | |
Data: | 2022 |
Editor: | Elsevier |
Cita bibliográfica: | European Journal of Pharmaceutics and Biopharmaceutics 172 (2022) 144-156 |
Resumo: | Nanostructured lipid carriers (NLC) are novel lipidic nanosystems that provide significant improvements in terms of high drug loading capacity and controlled drug release. The purpose of the present work was based on the design, development, and physicochemical characterization of lactoferrin-loaded NLCs as a new therapeutic alternative for the keratoconus treatment. Lactoferrin-loaded NLCs were successfully prepared by a double emulsion/solvent evaporation method. The resultant NLC were assessed in terms of particle size, size distribution, surface charge, morphology, encapsulation efficiency (EE), loading capacity (LC), stability, cytotoxicity, in vitro release, and ocular surface retention. Resulting data showed a size of 119.45 ± 11.44 nm, a 0.151 ± 0.045 PDI value and a surface charge of −17.50 ± 2.53 mV. Besides, high EE and LC values were obtained (up to 75%). The in vitro release study demonstrated a lactoferrin controlled release pattern. NLCs were also stable, non-toxic and show mucoadhesive properties. Thus, a consistent preclinical base was obtained, where NLC may be considered as a potential controlled release novel drug delivery system of lactoferrin for the keratoconus treatment |
Versión do editor: | https://doi.org/10.1016/j.ejpb.2022.02.010 |
URI: | http://hdl.handle.net/10347/29014 |
DOI: | 10.1016/j.ejpb.2022.02.010 |
E-ISSN: | 0939-6411 |
Dereitos: | 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/) Atribución 4.0 Internacional |
Coleccións
-
- EST-Artigos [123]
- FTF-Artigos [274]
O ítem ten asociados os seguintes ficheiros de licenza: